## Figures

## Abstract

Epitope-based vaccines (EVs) have a wide range of applications: from therapeutic to prophylactic approaches, from infectious diseases to cancer. The development of an EV is based on the knowledge of target-specific antigens from which immunogenic peptides, so-called epitopes, are derived. Such epitopes form the key components of the EV. Due to regulatory, economic, and practical concerns the number of epitopes that can be included in an EV is limited. Furthermore, as the major histocompatibility complex (MHC) binding these epitopes is highly polymorphic, every patient possesses a set of MHC class I and class II molecules of differing specificities. A peptide combination effective for one person can thus be completely ineffective for another. This renders the optimal selection of these epitopes an important and interesting optimization problem. In this work we present a mathematical framework based on integer linear programming (ILP) that allows the formulation of various flavors of the vaccine design problem and the efficient identification of optimal sets of epitopes. Out of a user-defined set of predicted or experimentally determined epitopes, the framework selects the set with the maximum likelihood of eliciting a broad and potent immune response. Our ILP approach allows an elegant and flexible formulation of numerous variants of the EV design problem. In order to demonstrate this, we show how common immunological requirements for a good EV (e.g., coverage of epitopes from each antigen, coverage of all MHC alleles in a set, or avoidance of epitopes with high mutation rates) can be translated into constraints or modifications of the objective function within the ILP framework. An implementation of the algorithm outperforms a simple greedy strategy as well as a previously suggested evolutionary algorithm and has runtimes on the order of seconds for typical problem sizes.

## Author Summary

Over the last decade the design of tailor-made vaccines for prophylactic applications (e.g., prevention of infection) and therapeutic applications (e.g., cancer therapy) has attracted significant interest. Epitope-based vaccines are good candidates for such tailor-made approaches. They trigger an immune response by confronting the immune system with immunogenic peptides derived from, e.g., viral- or cancer-specific proteins. These peptides bind to major histocompatibility complex (MHC) molecules in a specific manner. The resulting complex is crucial for immune system activation. However, there are many allelic variants of MHC molecules, meaning that different patients typically bind different repertoires of peptides. Nevertheless, due to economical and regulatory issues one cannot simply add all immunogenic peptides to such a peptide mix. Hence, it is crucial to identify the optimal set of peptides for a vaccine, given constraints such as MHC allele frequencies in the target population, peptide mutation rates, and maximum number of selected peptides. In this work we formalize this problem, and variants thereof, in a mathematical framework. The resulting optimization problem can be solved efficiently and yields a provably optimal peptide combination. We can show that the method performs better than existing solutions. Furthermore, the framework is highly flexible and can easily handle additional criteria.

**Citation: **Toussaint NC, Dönnes P, Kohlbacher O (2008) A Mathematical Framework for the Selection of an Optimal Set of Peptides for Epitope-Based Vaccines. PLoS Comput Biol 4(12):
e1000246.
https://doi.org/10.1371/journal.pcbi.1000246

**Editor: **Rob J. De Boer, Utrecht University, Netherlands

**Received: **August 19, 2008; **Accepted: **November 6, 2008; **Published: ** December 26, 2008

**Copyright: ** © 2008 Toussaint et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and
source are credited.

**Funding: **This work was funded in part by the Deutsche Forschungsgemeinschaft (Grant
SFB685/B1).

**Competing interests: ** The authors have declared that no competing interests exist.

## Introduction

The development of vaccines and their subsequent large-scale prophylactic use was undoubtedly one of the most important developments in medicine. Vaccines make use of the adaptive part of the human immune system to protect from future infections (e.g., prophylactic vaccines used against viruses) as well as to fight chronic diseases and cancer.

Cellular adaptive immunity is, at its core, triggered by the recognition of
immunogenic peptides bound to MHC class I (MHC I) and II molecules by T-cell
receptors located on the surface of T cells. These peptides are derived from
antigens, i.e., proteins that can cause an immune response, as a result of rather
complex antigen processing pathways *in vivo*. Peptides capable of
causing such an immune response are called epitopes and represent the smallest
subunits that may be used therapeutically.

There are numerous options for constructing a vaccine once a set of potential
antigens is known. The antigens or parts thereof can be used as intact proteins
[1],[2], they can be administered as RNA or DNA coding for
the antigen [3],[4], or the
epitopes contained in the antigens may be used for vaccines. As discussed in detail
in [5]
the use of epitope-based vaccines (EVs) brings about manifold advantages, e.g.,
safety, ease of production, analytical control, and distribution. Skilled selection
of epitopes can precisely direct the evoked immune response at conserved and highly
immunogenic regions of several antigens. Due to these advantages and the
applicability in personalized vaccination, EVs have recently been getting more and
more attention. The recent review of EVs by Purcell *et al.*
[5] gives
a good overview of the state of the art as well as its achievements. We will thus
only point out some recent studies.

EVs have proven successful in preclinical trials in mice [6], on which many of the preliminary studies have been conducted. A large number of clinical studies, both from academia and industry, have also been successful and have entered and/or completed clinical phase I and II trials [7]–[11]. Several commercial products have now entered clinical phase III trials. The indications for the vaccines in trial are mostly various cancers (e.g., leukemia, colorectal cancer, gastric cancer, lung cancer) and infectious diseases (predominantly HIV and hepatitis C virus).

The design of an EV entails one critical step, the selection of the epitopes. From the set of antigens, one can experimentally determine or computationally predict epitopes for a variety of MHC alleles. The crucial task is to select the set of epitopes which yields the best immune response in a given population while at the same time keeping the number of epitopes low. This step is of course critical to the success of the vaccine. The selection is usually made on a case-by-case basis considering key properties for each epitope: overall immunogenicity, mutation tolerance, population coverage, antigen coverage, and antigen processing.

The selection methods used by the pharmaceutical industry are manifold. In 2004,
Singh-Jasuja *et al.* presented the Tübingen approach [12] to
acquire an experimentally validated initial list of epitopes from tumor associated
antigens. In this work, the incorporation of computational methods for prediction of
MHC-peptide binding in the process is proposed. Since they help to reduce the number
of experiments to be performed, such prediction methods have become standard tools
in immunology. Commonly used methods are SYFPEITHI [13], HLA_BIND/Bimas
[14],
SVMHC [15],
NetMHC [16]–[18], EpiMatrix [19], and
the methods [20]–[23] provided by the
Immune Epitope Database [24].

Given the set of candidate peptides, computational methods can be used to determine
the relevant attributes of each candidate. However, the final choice of the set of
epitopes to be used in the vaccine is typically performed manually. Several groups
have addressed this problem computationally. In 2005, DeGroot *et al.*
[25]
published an approach to creating highly immunogenic and conserved epitopes to be
used in EVs. The authors use EpiMatrix [19] to estimate the MHC
class II binding affinity of highly conserved 9mers from HIV-1 proteins. Peptides
with high binding affinities are then used to construct extended peptides containing
multiple overlapping 9mers. *In vitro* evaluation of the
immunogenicity of a selected set of these extended peptides yielded positive
results.

Recently, Vider-Shalit *et al.*
[26]
proposed using a genetic algorithm to design an ordered sequence of epitopes to be
used in an EV. Information on peptide conservation and similarity to self-peptides
is used to pre-filter the set of candidates, while information on MHC allele
frequencies is used to select alleles of interest. The scoring function used for the
heuristic takes into account the number of covered MHC alleles, the number of
covered antigens, the number of covered MHC/antigen combinations, and the
probability of each epitope to be properly cleaved in the sequence.

Two related approaches were published by Fischer *et al.*
[27] and
Nickle *et al.*
[28]. Both
groups focus on designing vaccine antigens capable of protecting against diverse
HIV-1 strains. In order to do so, they use computational methods to compress the
variation found in naturally occurring antigens into a small number of composite
antigens.

Common to the computational approaches above (and of course manual selection) is the
fact that the solutions are not necessarily optimal. None of the approaches can
guarantee that there is not a better vaccine possible from the given set of
epitopes. In this work we propose an integer linear programming approach to finding
a provably optimal set of epitopes for an EV. Given a set of candidate peptides, a
set of MHC alleles of interest, information on the peptides' respective
immunogenicities along with other information to be incorporated into the selection
process, our framework is capable of finding the set of epitopes yielding the
highest possible overall immunogenicity (Figure 1). The resulting integer linear program
can be solved very efficiently for all practical problem sizes (runtimes of a few
seconds) and can thus be readily applied. With respect to various quality criteria
(population coverage, antigen coverage, overall immunogenicity), the approach
outperforms a simple greedy heuristic (‘pick the *k* best
epitopes’) and also a genetic algorithm. The elegant mathematical
formulation turns out to be flexible enough to also account for variants of the
problem, e.g., the application to personalized vaccines. To our knowledge, this is
the first epitope selection framework that finds the optimal solution.

Starting from target antigens, a list of properties of interest, and a target population the information necessary to determine an optimal set of epitopes is derived (gray boxes). Given this information, a mathematical framework can conveniently be used to find the set of epitopes that is optimal with respect to the target population and the properties of interest.

## Materials and Methods

### Approach

In order to find an optimal set of epitopes, we first have to define what
characterizes a *good* vaccine or, correspondingly, a
*good* set of epitopes. This issue is highly controversial in
the literature and only large-scale data from vaccination trials will provide
sufficient data to validate the different approaches retrospectively. With this
in mind, we do not suggest one optimal epitope selection strategy, but instead
suggest a mathematical framework that allows working with various definitions of
the term ‘good vaccine’. For a chosen definition, however,
the algorithms will yield a combination of epitopes that is provably optimal.

In the following, we will introduce a ‘reasonable’ definition of a good vaccine. This will allow us to present the mathematical formulation and to illustrate how immunological requirements can be translated into mathematical constraints. For specific applications, the requirements and constraints may of course deviate from those given. For example, sequence variation in an antigen would be much more important for an HIV vaccine than for a cancer vaccine. The framework is flexible enough to allow for such different requirements, as we will illustrate towards the end of the work.

A good vaccine displays a high overall immunogenicity, which means it is capable of inducing potent immunity in a large fraction of the target population. This basic definition forms the basis of our mathematical formulation which aims at maximizing overall immunogenicity of the selected epitopes. We extend this definition by additionally requiring high mutation tolerance as well as a certain degree of allele and antigen coverage. Furthermore, the selected epitopes should display a high probability of passing through the antigen processing pathway. We thus obtain a brief list of basic requirements:

#### Mutation tolerance.

Mutations within the targeted antigen regions can lead to an escape from immune response. High genetic variability as observed in, e.g., HIV, the hepatitis C virus, and influenza can thus affect protection by a vaccine. Selection of highly conserved non-overlapping epitopes reduces the chance of immune escape.

#### Allele coverage.

Because the MHC is polygenic, every individual possesses a set of MHC loci. Due to the high polymorphicity of these loci, the pool of MHC molecules varies from individual to individual. The allelic form of an MHC molecule determines the spectrum of peptides the molecule can bind. Within a population alleles occur with different frequencies. Hence, requiring a certain number of alleles to be covered is equivalent to requiring a certain degree of population coverage. An MHC allele is said to be covered by a set of epitopes if at least one of the epitopes is capable of inducing an immune response when bound to the corresponding MHC molecule.

#### Antigen coverage.

The expression frequencies of viral proteins differ. Selecting epitopes from a wide variety of antigens increases the chance of detecting a virus at any developmental stage.

#### Antigen processing.

Before a peptide is presented by an MHC molecule on the cell surface it passes through an antigen processing pathway, which includes proteasomal cleavage and TAP transport. Knowledge of these steps' specificities allows exclusion of peptides which are unlikely to ever be presented to a T cell.

From all possible epitope combinations, the ones with a maximum overall immunogenicity will be called ‘optimal’ (there may be more than one optimal epitope combination). Hence, the search for an optimal epitope set for an EV can be interpreted as an optimization problem: out of a given set of epitopes, choose a subset which, out of all subsets meeting the above-named requirements, displays maximum overall immunogenicity. Since health agencies such as the FDA require proof of the effectiveness and safety of every individual component of a vaccine, the size of such a subset is usually kept rather small (up to a dozen peptides).

### Mathematical Abstraction

Given a set of epitopes and a set of MHC alleles we assume a linear relationship
to exist between (a) the immune response induced by all epitopes with respect to
all alleles and (b) the immune responses induced by every single one of the
epitopes with respect to each of the alleles. Thus, the overall immunogenicity
of a set of epitopes depends on the immunogenicity of its components with
respect to the different MHC alleles. Furthermore, the contribution of an allele
directly depends on its probability of occurring within the target population.
(In this context *probability* is commonly referred to as
*frequency*. We use *probability* since it is
the mathematically correct term.) More common alleles are weighted more than
uncommon ones. Thus, overall immunogenicity *I* can be derived
mathematically as a weighted sum over immunogenicities of epitopes
*E* with respect to the given MHC alleles *A*:where *p _{a}* corresponds to the
probability of allele

*a*in the target population and

*i*

_{e}_{,a}to a measure of the immunogenicity of epitope

*e*when bound to allele

*a*(either experimentally determined or predicted).

### Integer Linear Programming

Our goal is to maximize overall immunogenicity while constraining the possible solutions to sets of peptides which satisfy the above mentioned requirements for a good vaccine. This problem can be conveniently formulated as an integer linear program (ILP). Linear programming deals with the optimization of linear objective functions subject to linear constraints [29]. An ILP is a linear program with integral unknowns. While linear programs without integral unknowns can be solved efficiently, ILPs are NP-complete. Nevertheless, there are tools available that find optimal solutions quite efficiently.

We restate the problem of choosing the optimal set of epitopes as an ILP. Solving the ILP will render an optimal solution according to our definition of an optimal epitope set. (Adapting the ILP to a different definition is straightforward.) For the sake of clarity, we start out with the very basic definition of an optimal epitope set. In the next step the resulting ILP will be extended to represent the more refined definition.

The set of candidate epitopes is *E*. Each epitope
*e*∈*E* is associated with a binary
decision variable x_{e}, where
*x _{e}* = 1 if the
respective epitope belongs to the optimal set and

*x*= 0 otherwise. The ILP corresponding to the basic definition of an optimal epitope set is shown in Table 1. This ILP maximizes overall immunogenicity: epitope immunogenicity with respect to a specific MHC allele is weighted by the allele's probability. The only constraint is the number of epitopes to select.

_{e}We will now extend this basic ILP to represent a more refined definition of a
good epitope set. In order to implement the additional requirements we introduce
another set of binary decision variables: each MHC allele *a* is
associated with a variable y_{a}. If allele *a* is
covered, meaning that an epitope which is sufficiently immunogenic with respect
to allele *a* belongs to the optimal set,
y_{a} = 1, otherwise
y_{a} = 0. The extended ILP is shown in
Table 2. It accounts
for mutation tolerance by selecting only non-overlapping conserved epitopes, and
for allele and antigen coverage. Additional constraints prevent the selection of
peptides which are unlikely to result from antigen processing.

It might be desirable to obtain several optimal or nearly optimal epitope sets.
As proposed in [30], this can be achieved by adding the
constraints given in eq. (1), where *S _{j}* represents
the optimal set of epitopes found in iteration

*j*and

*s*represents the number of solutions to be obtained. The ILP has to be solved iteratively

*s*times. After each iteration, the ILP for the next iteration

*j*+1 is created by adding the corresponding constraint to the ILP of iteration

*j*.(1)

Every resulting epitope set differs from all other solutions in at least
*q* peptides,
1≤*q*≤*k*.

### Nonlinear Requirements

In order to incorporate a requirement into the ILP framework it must be formulated as a linear constraint. There are, however, reasonable requirements which are non-linear. These cannot be incorporated directly. It is possible though to search a sufficiently large set of optimal and suboptimal solutions for the best set of epitopes that yields the required properties—provided that the requirements are feasible. Two examples of reasonable non-linear requirements will be discussed below.

#### Example 1: Population coverage.

A major interest in vaccine design is population coverage: For what fraction
of a target population will the resulting EV be effective? In theory this
corresponds to the probability of an individual in the population carrying
at least one MHC allele covered by the epitopes in the EV. Given a set of
MHC alleles *A* as before and their distribution within a
population, the population coverage of a particular set of epitopes can be
computed. For this computation the polygenicity of the MHC has to be taken
into account. It is
*A* = *A*_{1}
∪…∪ *A _{m}* with

*A*being the alleles at locus

_{i}*i*. Let be the probability of an allele

*a*occurring at the corresponding MHC locus. Then the probability of an individual in the population carrying an allele from the set

*A*at locus

_{i}*i*corresponds toLet y

_{a}be as described above. It follows that the probability of an individual carrying at least one MHC allele covered by the epitopes in

*E*, and thus the population coverage of

*E*, is

#### Example 2: Average number of epitopes per individual.

Population coverage of an epitope set states what fraction of a population
carries an MHC allele associated with one of the epitopes. It does not give
any information on the number of active epitopes per individual. The number
of epitopes within a set which are active for a specific individual depends
on the individual's MHC genotype. Given the haploidic probabilities
of MHC alleles within a population the probability of MHC genotypes can be
calculated. Alleles not included in the set *A* are accounted
for by adding a representative allele *X* to each locus. The
frequency of the representative at locus *i* results from .

Let *G* be the set of genotypes within the population of
interest and *p _{g}* the probability of genotype

*g*. Furthermore, let

*b*be the number of epitopes in an epitope set

_{g}*E*which are immunogenic with respect to an MHC allele in

*g*. The average number of active epitopes per individual results from

### Evaluation

Vider-Shalit *et al.*
[26] applied their evolutionary-algorithm-based
vaccine design method to hepatitis C virus (HCV). We used our framework on
similar data and compared the results of both approaches.

#### Data.

HCV protein sequences (amino acid frame 1) for ten different proteins (C, E1,
E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B) and four different subtypes (1a,
1b, 2a, 3a) were retrieved from the Los Alamos hepatitis C sequence database
[31]. For each protein of each subtype a multiple
sequence alignment (MSA) was created using MUSCLE [32], resulting in 40
MSAs. From each MSA a consensus sequence was created. All 9mers from these
consensus sequences were regarded as potential epitopes. *In
silico* predicted MHC binding affinities using BIMAS matrices [14]
are utilized as a measure of immunogenicity. MHC alleles, their probability
of occurring in the human population, and binding affinity score thresholds
were directly taken from Vider-Shalit *et al.* To allow a
comparison of our results with those of Vider-Shalit *et
al.*, we adopt their simplistic definition of peptide conservation
(A peptide is considered to be at least *x*%
conserved if all of its amino acids display a conservation of at least
*x*%.) and disregard all insufficiently
conserved (<90%) peptides. To score the probability of a
peptide being a result of antigen processing, we used the proteasomal
cleavage matrix from the supplementary material of [26]. As noted
in several places, the influence of TAP transport is often rather limited
[26],[33]. Consideration
of TAP transport is thus omitted for this example.

It has to be noted that the accuracies of the prediction methods cause some limitations. MHC-peptide binding can be predicted with relatively high accuracy for many alleles, whereas proteasomal cleavage prediction leaves more room for improvement.

#### Incorporating the scoring function.

The scoring function *S* of Vider-Shalit *et
al.* takes into account the number of covered MHC alleles, the
number of covered antigens, the number of covered MHC/antigen combinations,
and a score for the probability of each epitope in the ordered sequence
being properly cleaved:Here, *s* represents the ordered sequence of
epitopes to be scored. In order to show the flexibility of our approach we
incorporate aspects of this function in our ILP. Since the aim of our
framework is to select a set of epitopes and not to create an epitope
sequence, we omit the factor *p*(*cleave*).

Binary variables have to be introduced in order to count the number of
covered antigens and the number of covered MHC/antigen combinations:
z_{i} = 1 if an epitope from the
*i*-th antigen belongs to the optimal set and
z_{i} = 0 otherwise.
w_{a,i} = 1 if an epitope from the
*i*-th antigen, which is sufficiently immunogenic with
respect to MHC allele *a*, belongs to the optimal set and
w_{a,i} = 0 otherwise. Since
immunogenicity scores tend to be higher than the weighted sums of the
coverage scores and would therefore outweigh them, we scale the
immunogenicity by a (purely empirical) factor of 0.1. The resulting ILP
still aims at high overall immunogenicity while at the same time extending
the coverage of antigens, MHC alleles, and MHC/antigen combinations. The ILP
is shown in Table 3.

### Implementation

We used ILOG CPLEX 9.1 [34] with its C++ interface ILOG Concert Technology 2.1 to formulate and solve the ILP. It is, however, possible to solve the ILPs with most other ILP solvers, e.g., MOSEK [35] or freely available packages like SCIP [36],[37].

A formulation of the extended ILP (Table 2) as ILOG CPLEX input, the required data for the comparison
with Vider-Shalit *et al.*
[26] as well as the corresponding ILOG CPLEX output
can be found in the supplementary material (Texts S1,
S2,
S3).

## Results

### Immunogenicity

In order to show the effectiveness of the above-mentioned approach, we compare our strategy with other published approaches and determine the theoretical gain in immunogenicity or the number of epitopes required to achieve a similar immunogenicity. While an experimental validation of this approach would be valuable, it is beyond the scope of this paper, which focuses on the theoretical foundations of the epitope selection. We compare our optimal strategy (best overall immunogenicity, BOI) with two simple approaches:

- randomly select
*k*peptides out of a pool of good epitopes (random set of epitopes, RSE) and - a simple greedy approach: pick the
*k*best epitopes from the set (best epitope-wise immunogenicity, BEI).

These three epitope selection strategies were used to select different-sized sets
of epitopes from a set of 4461 conserved (≥90%) HCV 9mers. For
BOI the basic ILP (Table
1) was used to maximize overall immunogenicity. BEI selects the epitopes
with the highest sum of immunogenicities irrespective of the probabilities of
the corresponding MHC alleles. The overall immunogenicity of each epitope set
was determined and is displayed in Figure 2. For RSE, mean and standard deviation of 100 random
selections of different-sized epitope sets from the 100 most immunogenic
peptides are shown. The BEI curve shows sudden increases in overall
immunogenicity from 0 to 1, 10 to 13, and from 20 to 21 epitopes. This is caused
by the selection of epitopes which are highly immunogenic with respect to
HLA-A*0201, which is the most common
(*p ^{L}* = 0.145) among
the considered alleles. All other selected epitopes are highly immunogenic with
respect to less common alleles like HLA-B*2705
(

*p*= 0.015) or HLA-B*5102 (

^{L}*p*= 0.003). Thus the former contribute more extensively to the overall immunogenicity than the latter.

^{L}(A) Overall immunogenicity of different-sized epitope sets. (B) Overall immunogenicity of a set of 10 epitopes. (C) Number of epitopes required to achieve an overall immunogenicity of at least 2,699.

The average overall immunogenicity of the randomly chosen epitope sets is rather low: scores range from about 308 for five epitopes, to 1,763 for 25 epitopes, to 2,699 for 40 epitopes. The other two approaches start from a minimum overall immunogenicity of more than 900 and reach immunogenicities of 4,502 (BEI) and 6,142 (BOI), respectively. To achieve an immunogenicity of at least 2,699, BOI requires five and BEI 12 epitopes (Figure 2).

For sets with more than one epitope, the scores yielded by the BOI strategy are between about 20% (13 epitopes) and 120% (6 epitopes) higher than those of the BEI strategy.

### Comparison with Vider-Shalit *et al.* on HCV

In order to compare our approach to the work of Vider-Shalit *et al.*
[26] we applied the ILP given in Table 2 to the HCV data and
27 of the 29 alleles from [26]. The alleles HLA-B^{*}0702
and HLA-B^{*}3501 were omitted, since none of the candidate
peptides binds to them. Probably due to an error in sequence processing
(personal communication with Yoram Louzoun), a peptide (AALENLVTL) which does
not belong to any of the proteins under consideration was included in the 25
epitopes selected by Vider-Shalit *et al.* We exclude this
peptide and base our comparison on sets of 24 epitopes.

For the 24 epitopes to be selected, we require a minimum conservation of
90%, an allele coverage of 27, and an antigen coverage of at least
one epitope per antigen. Furthermore, only epitopes with antigen processing
scores within the top 30% of all sufficiently conserved candidate
peptides were allowed to be selected. The following 24 epitopes (hereafter
*E _{ILP}*) were selected:

SFSIFLLAL^{*} | GHRMAWDMM^{+} | VYEADDVIL |

YLYDHLAPM | GLRDLAVAV^{+} | GPTPLLYRL^{+} |

QYLAGLSTL^{+} | NFVSGIQYL | VLSDFKTWL^{*} |

GLYLFNWAV | ALYDVVSTL^{*} | RRCRASGVL^{+} |

CFTPSPVVV^{+} | FLLLADARV^{*} | GPADGMVSK^{+} |

TWVLVGGVL^{+} | IELGGKPAL^{+} | LAGGVLAAV |

ARPDYNPPL^{+} | KLLPRLPGV | RHTPVNSWL^{+} |

WPLLLLLLA | VTYSLTGLW | YFVIFFVAA |

Four epitopes (marked with *) are known HCV epitopes and can be found in
the Immune Epitope Database (IEDB, release 2008_4_1_3_28) [24]. Another 11
epitopes (marked with +) are contained in known longer epitopes. The
overall immunogenicity of the selected set is 2,549. It includes binders for all
27 alleles with all 40 antigens being represented and covers 22.7% of
all MHC/antigen combinations. The average number of epitopes per individual of
the population is 13.3. The corresponding values of the epitope set selected by
Vider-Shalit *et al.* (hereafter *E _{VS}*)
are listed in Table 4.

To improve the MHC/antigen coverage while still aiming at high overall
immunogenicity we included the central part of the scoring function of
Vider-Shalit *et al.* in the objective function of our ILP. The
optimal epitope set with respect to the modified objective function (hereafter
*E _{Comb}*) is only 15% less
immunogenic than the original epitope set

*E*and more than 17 times more immunogenic than

_{ILP}*E*. As for MHC/antigen coverage, it outperforms both (Table 4).

_{VS}*E*includes one epitope which is already known and 14 epitopes which are contained in longer epitopes listed in the IEDB. Figure 3 shows that when using the combined objective function, 18 epitopes suffice to cover all alleles and antigens and furthermore to outperform

_{Comb}*E*in terms of immunogenicity (371) and MHC/antigen coverage (22.8%).

_{VS}(A) Overall immunogenicity. (B) Coverage of MHC/antigen pairs.

## Discussion

The selection of an epitope set with very high overall immunogenicity is crucial for the efficacy of an EV. Depending on the number of candidate epitopes to choose from, the number of alleles to be considered, as well as on the additional requirements, this problem can become very complex. In this work we propose a mathematical framework that can be used to solve this problem quickly for practical problem sizes. For several characteristic examples, we show that immunological requirements can be conveniently formulated as an ILP. The solution of this ILP yields an optimal set of epitopes: the set of epitopes that displays the highest overall immunogenicity of all sets which meet the pre-defined requirements. To our knowledge, this is the only approach that yields provably optimal solutions to the vaccine design problem for EVs. In contrast to previous heuristics, the optimal solution yields either significantly better overall immunogenicity for the same number of epitopes or a smaller number of required epitopes to reach the same level of immunogenicity. The flexibility of the framework allows selecting other objective functions, too, for example, maximizing antigen or allele coverage.

The optimal selection of epitopes yields—in theory—significantly higher overall immunogenicities than other strategies (e.g., selection of the best epitopes or evolutionary algorithms). However, one should keep in mind that the selection of the epitopes is still a difficult and controversial issue since the underlying processes are not yet fully understood. In particular, the interplay of different epitopes poses a difficult problem. Competition between epitopes will probably result in reduced immunogenicity of peptide cocktails, an effect that has been observed in various studies.

On the one hand, this represents a problem, because the assumption of independence between epitopes is one of the key assumptions made in this work (and in all related approaches). Lacking an accurate model of these competition effects, however, it seems like the best assumption one can make. On the other hand, the effects of competition are a compelling reason to employ this type of selection approach. Competition effects will be less severe for fewer peptides, therefore a selection procedure that yields the same overall immunogenicity with fewer peptides can in fact mitigate this problem. Assuming that competition primarily arises between epitopes binding to the same MHC allele, one can also introduce additional constraints to reduce competition (e.g., find the best combination that contains at most two epitopes per allele). In the long run, a thorough quantitative analysis of larger vaccination studies might shed some light on these effects and their importance.

Also, the notion of immunogenicity alone, or the ability to evoke an immune response
in a certain fraction of patients, is not necessarily a true measure of quality for
a vaccine. In their recent review on the quality of the T-cell response [38], Seder
*et al.* argue that protective T-cell responses are too complex
to be sufficiently described by a measure of magnitude alone. An adequate metric
would thus not only account for the magnitude but also for the multifunctional
quality of the response. The flexibility of our framework allows for the
incorporation of a different quality measure for immunogenicity and a careful
comparison of the peptide cocktails suggested by different objective functions would
be very interesting.

In their review of EVs, Purcell *et al.*
[5] point
out that, to date, there are no human EVs on the market. This is mainly attributed
to the difficulties associated with peptide stability and delivery. Various delivery
strategies [39] are being explored in clinical studies. In an
extension of this work, one might therefore also include considerations related to
the peptide delivery. For *beads-on-a-string* type vaccines, the
selected epitopes are combined into one larger polypeptide. As the specificities of
the antigen processing pathway have to be taken into account when constructing the
polypeptide, the order of the epitopes as well as possible spacer sequences need to
be optimized (e.g. through incorporation of a proteasomal cleavage matrix).

## Supporting Information

### Text S1.

ILOG CPLEX input. AMPL formulation of the extended ILP given in Table 2 adapted for the comparison with Vider-Shalit et al.

https://doi.org/10.1371/journal.pcbi.1000246.s001

(3.00 KB TXT)

### Text S2.

HCV data (in AMPL format) used for the comparison with Vider-Shalit et al. Only highly conserved peptides (> = 90%) were considered when generating this file.

https://doi.org/10.1371/journal.pcbi.1000246.s002

(1.70 MB TXT)

## Author Contributions

Conceived and designed the experiments: NCT PD OK. Performed the experiments: NCT. Analyzed the data: NCT OK. Wrote the paper: NCT PD OK.

## References

- 1. Moutschen M, Léonard P, Sokal EM, Smets F, Haumont M, et al. (2007) Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 25: 4697–4705.M. MoutschenP. LéonardEM SokalF. SmetsM. Haumont2007Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.Vaccine2546974705
- 2. Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, et al. (2007) Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 25: 510–518.PA GoepfertGD TomarasH. HortonD. MontefioriG. Ferrari2007Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.Vaccine25510518
- 3. Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, et al. (2006) Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage nonsmall-cell lung cancer. Mol Ther 13: 1185–1191.J. NemunaitisT. MeyersN. SenzerC. CunninghamH. West2006Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage nonsmall-cell lung cancer.Mol Ther1311851191
- 4. Mancini-Bourgine M, Fontaine H, Bréchot C, Pol S, Michel ML (2006) Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 24: 4482–4489.M. Mancini-BourgineH. FontaineC. BréchotS. PolML Michel2006Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers.Vaccine2444824489
- 5. Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6: 404–414.AW PurcellJ. McCluskeyJ. Rossjohn2007More than one reason to rethink the use of peptides in vaccine design.Nat Rev Drug Discov6404414
- 6. Depil S, Moralès O, Castelli FA, Delhem N, François V, et al. (2007) Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies. J Immunother 30: 215–226.S. DepilO. MoralèsFA CastelliN. DelhemV. François2007Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies.J Immunother30215226
- 7. Chianese-Bullock KA, Irvin WP, Petroni GR, Murphy C, Smolkin M, et al. (2008) A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 31: 420–430.KA Chianese-BullockWP IrvinGR PetroniC. MurphyM. Smolkin2008A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.J Immunother31420430
- 8. Kenter GG, Welters MJP, Valentijn ARPM, Lowik MJG, van der Meer DMAB, et al. (2008) Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 14: 169–177.GG KenterMJP WeltersARPM ValentijnMJG LowikDMAB van der Meer2008Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.Clin Cancer Res14169177
- 9. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, et al. (2005) Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11: 5900–5911.N. YajimaR. YamanakaT. MineN. TsuchiyaJ. Homma2005Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.Clin Cancer Res1159005911
- 10. Slingluff CL, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, et al. (2003) Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21: 4016–4026.CL SlingluffGR PetroniGV YamshchikovDL BarndS. Eastham2003Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.J Clin Oncol2140164026
- 11. Slingluff CL, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, et al. (2007) Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 13: 6386–6395.CL SlingluffGR PetroniKA Chianese-BullockME SmolkinS. Hibbitts2007Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.Clin Cancer Res1363866395
- 12. Singh-Jasuja H, Emmerich NPN, Rammensee HG (2004) The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother 53: 187–195.H. Singh-JasujaNPN EmmerichHG Rammensee2004The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy.Cancer Immunol Immunother53187195
- 13. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213–219.H. RammenseeJ. BachmannNP EmmerichOA BachorS. Stevanovic1999SYFPEITHI: database for MHC ligands and peptide motifs.Immunogenetics50213219
- 14. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152: 163–175.KC ParkerMA BednarekJE Coligan1994Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.J Immunol152163175
- 15. Dönnes P, Kohlbacher O (2006) SVMHC: a server for prediction of MHC-binding peptides. Nucleic Acids Res 34: W194–W197.P. DönnesO. Kohlbacher2006SVMHC: a server for prediction of MHC-binding peptides.Nucleic Acids Res34W194W197
- 16. Buus S, Lauemøller SL, Worning P, Kesmir C, Frimurer T, et al. (2003) Sensitive quantitative predictions of peptide-MHC binding by a ‘Query by Committee’ artificial neural network approach. Tissue Antigens 62: 378–384.S. BuusSL LauemøllerP. WorningC. KesmirT. Frimurer2003Sensitive quantitative predictions of peptide-MHC binding by a ‘Query by Committee’ artificial neural network approach.Tissue Antigens62378384
- 17. Nielsen M, Lundegaard C, Worning P, Lauemøller SL, Lamberth K, et al. (2003) Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 12: 1007–1017.M. NielsenC. LundegaardP. WorningSL LauemøllerK. Lamberth2003Reliable prediction of T-cell epitopes using neural networks with novel sequence representations.Protein Sci1210071017
- 18. Nielsen M, Lundegaard C, Worning P, Hvid CS, Lamberth K, et al. (2004) Improved prediction of MHC class I and class II epitopes using a novel gibbs sampling approach. Bioinformatics 20: 1388–1397.M. NielsenC. LundegaardP. WorningCS HvidK. Lamberth2004Improved prediction of MHC class I and class II epitopes using a novel gibbs sampling approach.Bioinformatics2013881397
- 19. Schafer JR, Jesdale BM, George JA, Kouttab NM, Groot ASD (1998) Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Vaccine 16: 1880–1884.JR SchaferBM JesdaleJA GeorgeNM KouttabASD Groot1998Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix.Vaccine1618801884
- 20. Bui HH, Sidney J, Peters B, Sathiamurthy M, Sinichi A, et al. (2005) Automated generation and evaluation of specific mhc binding predictive tools: Arb matrix applications. Immunogenetics 57: 304–314.HH BuiJ. SidneyB. PetersM. SathiamurthyA. Sinichi2005Automated generation and evaluation of specific mhc binding predictive tools: Arb matrix applications.Immunogenetics57304314
- 21. Peters B, Sette A (2005) Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 6: 132.B. PetersA. Sette2005Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method.BMC Bioinformatics6132
- 22. Nielsen M, Lundegaard C, Lund O (2007) Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 8: 238.M. NielsenC. LundegaardO. Lund2007Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method.BMC Bioinformatics8238
- 23. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, et al. (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17: 555–561.T. SturnioloE. BonoJ. DingL. RaddrizzaniO. Tuereci1999Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices.Nat Biotechnol17555561
- 24. Peters B, Bui HH, Frankild S, Nielson M, Lundegaard C, et al. (2006) A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput Biol 2: e65.B. PetersHH BuiS. FrankildM. NielsonC. Lundegaard2006A community resource benchmarking predictions of peptide binding to MHC-I molecules.PLoS Comput Biol2e65
- 25. Groot ASD, Marcon L, Bishop EA, Rivera D, Kutzler M, et al. (2005) HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine 23: 2136–2148.ASD GrootL. MarconEA BishopD. RiveraM. Kutzler2005HIV vaccine development by computer assisted design: the GAIA vaccine.Vaccine2321362148
- 26. Vider-Shalit T, Raffaeli S, Louzoun Y (2007) Virus-epitope vaccine design: informatic matching the HLA-I polymorphism to the virus genome. Mol Immunol 44: 1253–1261.T. Vider-ShalitS. RaffaeliY. Louzoun2007Virus-epitope vaccine design: informatic matching the HLA-I polymorphism to the virus genome.Mol Immunol4412531261
- 27. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, et al. (2007) Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13: 100–106.W. FischerS. PerkinsJ. TheilerT. BhattacharyaK. Yusim2007Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.Nat Med13100106
- 28. Nickle DC, Rolland M, Jensen MA, Pond SLK, Deng W, et al. (2007) Coping with viral diversity in HIV vaccine design. PLoS Comput Biol 3: e75.DC NickleM. RollandMA JensenSLK PondW. Deng2007Coping with viral diversity in HIV vaccine design.PLoS Comput Biol3e75
- 29.
Schrijver A (1986) Theory of linear and integer programming. New York: John Wiley & Sons. A. Schrijver1986Theory of linear and integer programmingNew YorkJohn Wiley & Sons
- 30. Kingsford CL, Chazelle B, Singh M (2005) Solving and analyzing side-chain positioning problems using linear and integer programming. Bioinformatics 21: 1028–1036.CL KingsfordB. ChazelleM. Singh2005Solving and analyzing side-chain positioning problems using linear and integer programming.Bioinformatics2110281036
- 31. Kuiken C, Yusim K, Boykin L, Richardson R (2005) The Los Alamos hepatitis C sequence database. Bioinformatics 21: 379–384.C. KuikenK. YusimL. BoykinR. Richardson2005The Los Alamos hepatitis C sequence database.Bioinformatics21379384
- 32. Edgar RC (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32: 1792–1797.RC Edgar2004MUSCLE: multiple sequence alignment with high accuracy and high throughput.Nucleic Acids Res3217921797
- 33. Dönnes P, Kohlbacher O (2005) Integrated modeling of the major events in the MHC class I antigen processing pathway. Protein Sci 14: 2132–2140.P. DönnesO. Kohlbacher2005Integrated modeling of the major events in the MHC class I antigen processing pathway.Protein Sci1421322140
- 34.
ILOG, Inc (2005) ILOG CPLEX, version 9.1. ILOG, Inc2005ILOG CPLEX, version 9.1.
http://www.ilog.com
.
http://www.ilog.com
.
- 35.
MOSEK ApSMosek. MOSEK ApSMosek.
http://www.mosek.com
.
http://www.mosek.com
.
- 36.
Achterberg T (2007) Constraint Integer Programming. T. Achterberg2007Constraint Integer Programming.Ph.D. thesis, Technische Universität Berlin. Ph.D. thesis, Technische Universität Berlin.
- 37.
Achterberg T, Berthold T, Pfetsch M, Wolter KSCIP (Solving Constraint Integer Programs). T. AchterbergT. BertholdM. PfetschK. WolterSCIP (Solving Constraint Integer Programs).
http://scip.zib.de
.
http://scip.zib.de
.
- 38. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247–258.RA SederPA DarrahM. Roederer2008T-cell quality in memory and protection: implications for vaccine design.Nat Rev Immunol8247258
- 39. Sette A, Fikes J (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15: 461–470.A. SetteJ. Fikes2003Epitope-based vaccines: an update on epitope identification, vaccine design and delivery.Curr Opin Immunol15461470